Drugs / LY2300559
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01184508 | Jan 2011 → Apr 2012 | migraine disorder | Eli Lilly and Company | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2300559 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01184508 ↗ |
| Modality | Small molecule | — CHEMBL4297398 ↗ |
| Route | Oral | “Administered orally, once daily, for 12 weeks” NCT01184508 ↗ |